In December 2024, Western Europe’s PV selling rate continued its upward trend, reaching 13.1 million units/year. Year-on-year ...

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease ...

A ccording to preliminary estimates, Light Vehicle (LV) sales grew by 2.4% year-on-year (YoY) in December, to 1.51 million ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

In recent years, the oil and gas industry has progressed from using digital technologies for select use cases to making their ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary ...